常规实践中的结核病治疗监测检测:研究设计指南
该指南由临床微生物与感染杂志发布,针对常规临床诊疗中结核病治疗监测检测(TMT)的研究设计与评价提出建议,覆盖研究设计、招募、结局定义、参考标准、随访、临床场景、研究人群、治疗方案报告及指标检测与数据呈现八个领域,强调TMT准确性需在治疗全程多个时间点评估,且研究对象应为已确诊结核病者。
要点
- TMT应在治疗全程多个时间点评估准确性,而非仅用于疗程结束时判断治愈。
- 研究设计与结局定义须与所评价TMT的发展阶段相一致。
- 结核病治疗反应无参考标准,需根据TMT发展阶段选择不同参考标准与对照检测。
核心结论
- TMT应参照诊断检测的方式评价,但准确性须在治疗全程多个时间点评估,研究对象应为已确诊结核病者。
- 研究设计与结局定义须与所评价TMT的发展阶段相一致。
- 结核病治疗反应无参考标准,不同参考标准与对照检测的选择取决于TMT所处发展阶段。
- 使用对照检测有助于生成证据,报告时间点、TMT读数与分析结果时需清晰明确。
研究设计与样本
- 指南初稿基于结核病TMT系统综述中的经验形成,随后经小型内容专家组反馈、修订并征求跨领域实质专家意见。
主要发现
- 所提出的考虑与建议分为八个领域:研究设计与招募、结局定义、参考标准、参与者随访、临床场景、研究人群、治疗方案报告、指标检测与数据呈现。
关键数值与推荐
- TMT准确性须在治疗全程多个时间点评估。
- 研究对象应为已确诊结核病者。
- 研究设计与结局定义须与TMT发展阶段一致。
- 结核病治疗反应无参考标准,参考标准与对照检测的选择随TMT发展阶段而变化。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
SCOPE: The current tools for tuberculosis (TB) treatment monitoring, smear microscopy and culture, cannot accurately predict poor treatment outcomes. Research into new TB treatment monitoring tools (TMTs) is growing, but data are unreliable. In this article, we aim to provide guidance for studies investigating and evaluating TB TMT for use during routine clinical care. Here, a TB TMT would guide treatment during the course of therapy, rather than testing for a cure at the regimen's end. This article does not cover the use of TB TMTs as surrogate endpoints in the clinical trial context. METHODS: Guidelines were initially informed by experiences during a systematic review of TB TMTs. Subsequently, a small content expert group was consulted for feedback on initial recommendations. After revision, feedback from substantive experts across sectors was sought. QUESTIONS ADDRESSED BY THE GUIDELINE AND RECOMMENDATIONS: The proposed considerations and recommendations for studies evaluating TB TMTs for use during the treatment in routine clinical care fall into eight domains. We provide specific recommendations regarding study design and recruitment, outcome definitions, reference standards, participant follow-up, clinical setting, study population, treatment regimen reporting, and index tests and data presentation. Overall, TB TMTs should be evaluated in a manner similar to diagnostic tests, but TB TMT accuracy must be assessed at multiple timepoints throughout the treatment course, and TB TMTs should be evaluated in study populations who have already received a diagnosis of TB. Study design and outcome definitions must be aligned with the developmental phase of the TB TMT under evaluation. There is no reference standard for TB treatment response, so different reference standards and comparator tests have been proposed, the selection of which will vary depending on the developmental phase of the TMT under assessment. The use of comparator tests can assist in generating evidence. Clarity is required when reporting of timepoints, TMT read-outs, and analysis results. Implementing these recommendations will lead to higher quality TB TMT studies that will allow data to be meaningfully compared, thereby facilitating the development of novel tools to guide individual TB therapy and improve treatment outcomes.
引用
- MacLean EL, Zimmer AJ, den Boon S, et al. Tuberculosis treatment monitoring tests during routine practice: study design guidance. Clin Microbiol Infect. 2024. PMID: 38182047. doi:10.1016/j.cmi.2023.12.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。